Artios Pharma
Babraham, United Kingdom
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery, including the discovery and early development of the PARP inhibitor Olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the Crick Institute, London. Artios is building a pipeline of next-generation DDR programs to target hard to treat cancers, including its ATR inhibitor ART0380 in treating DDR defective tumors, which is in a Phase 1 clinical study, and the potential first-in-class Polθ inhibitor ART4215 for monotherapy and combination treatments.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2015
- Website
- www.artios.com/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of Artios Pharma?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now